Article The GERAS II Study

The GERAS II study was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers in Italy and Spain. Eligible patients were males and females aged ≥55 years old, who had received a diagnosis of probable AD according to the National Institute on Aging and Alzheimer’s Association and with a Mini-Mental State Examination (MMSE) score of 26 or less. At baseline, patients were stratified into groups based on AD severity as measured through their MMSE score (mild: MMSE 21-26, moderate: MMSE 15-20, and moderately severe/severe [MS/S]: MMSE < 15). Data collected for patients and caregivers included demographics/clinical characteristics; current medication; patient cognitive, functional and behavioral assessments; patient and caregiver health-related quality of life (HRQoL); and patient and caregiver resource use. The costs associated with the resources used were calculated. Costs were broken down into patient healthcare costs, patient social care costs and caregiver informal care costs. In Italy, 198 patients (29 mild; 80 moderate; 89 MS/S) were enrolled with mean age at baseline 77.5 years, 60% female. In Spain, a total of 380 participants (116 mild; 118 moderate; 146 MS/S) were enrolled with mean age 75.7 years, 63% female.

Manuscripts citing this dataset

  • Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study. 2017. DOI:
  • The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. 2013. DOI: 3233/JAD-122392

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.


Post a question or thought about this dataset here.